Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:COGTNASDAQ:KURANASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.68+1.4%$4.06$3.21▼$8.06$868.50M0.594.51 million shs4.96 million shsCOGTCogent Biosciences$7.24-0.3%$5.58$3.72▼$12.61$826.60M1.821.31 million shs3.12 million shsKURAKura Oncology$5.98+1.9%$6.18$5.41▼$23.48$508.19M0.41.24 million shs1.23 million shsRNAAvidity Biosciences$29.87+2.5%$30.57$21.51▼$56.00$3.51B0.951.39 million shs1.35 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+1.38%+3.66%-7.30%-26.98%-41.12%COGTCogent Biosciences-0.28%-4.99%+50.21%+11.90%-18.56%KURAKura Oncology+1.87%-3.55%+6.03%-16.25%-71.63%RNAAvidity Biosciences+2.47%+1.74%-2.32%-6.80%-24.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.1191 of 5 stars3.51.00.04.42.72.50.6COGTCogent Biosciences1.747 of 5 stars3.43.00.00.01.20.00.6KURAKura Oncology4.214 of 5 stars4.51.00.04.72.00.80.6RNAAvidity Biosciences2.3515 of 5 stars4.50.00.00.03.20.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.89195.89% UpsideCOGTCogent Biosciences 2.75Moderate Buy$14.57101.26% UpsideKURAKura Oncology 2.93Moderate Buy$24.50309.70% UpsideRNAAvidity Biosciences 3.06Buy$65.59119.58% UpsideCurrent Analyst Ratings BreakdownLatest COGT, KURA, ARDX, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025RNAAvidity BiosciencesSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.006/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/18/2025ARDXArdelyxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.006/17/2025COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/17/2025RNAAvidity BiosciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.006/11/2025RNAAvidity BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$65.006/10/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $75.006/10/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/10/2025RNAAvidity BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.006/9/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.006/9/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$65.00 ➝ $75.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M2.64N/AN/A$0.73 per share5.04COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AKURAKura Oncology$53.88M9.61N/AN/A$5.32 per share1.12RNAAvidity Biosciences$10.90M330.27N/AN/A$11.94 per share2.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A11.87N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)COGTCogent Biosciences-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)KURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)Latest COGT, KURA, ARDX, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.044.123.81COGTCogent BiosciencesN/A5.135.13KURAKura Oncology0.028.078.07RNAAvidity BiosciencesN/A16.9116.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%COGTCogent BiosciencesN/AKURAKura OncologyN/ARNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%COGTCogent Biosciences7.29%KURAKura Oncology6.40%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million227.77 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableRNAAvidity Biosciences190120.52 million115.90 millionOptionableCOGT, KURA, ARDX, and RNA HeadlinesRecent News About These CompaniesAvidity Biosciences (NASDAQ:RNA) Now Covered by Sanford C. BernsteinJune 25 at 2:12 AM | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. BernsteinJune 24 at 8:26 AM | marketbeat.comAvidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advanceJune 24 at 7:50 AM | investing.comSG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 23 at 3:20 AM | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027June 20, 2025 | investing.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in StockJune 19, 2025 | insidertrades.comWolfe Research Begins Coverage on Avidity Biosciences (NASDAQ:RNA)June 19, 2025 | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 SharesJune 18, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's WhyJune 17, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe ResearchJune 17, 2025 | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potentialJune 16, 2025 | investing.comAvidity Biosciences (NASDAQ:RNA) Shares Down 3.5% - Here's What HappenedJune 16, 2025 | marketbeat.comAssenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 15, 2025 | marketbeat.comRhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14, 2025 | marketbeat.comGAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)June 14, 2025 | marketbeat.comW. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockJune 12, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of RNA FY2026 EarningsJune 12, 2025 | marketbeat.comRaymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy RecommendationJune 12, 2025 | msn.comAvidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond JamesJune 11, 2025 | msn.comAvidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research CongressJune 11, 2025 | prnewswire.comCantor Fitzgerald Weighs in on RNA FY2026 EarningsJune 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOGT, KURA, ARDX, and RNA Company DescriptionsArdelyx NASDAQ:ARDX$3.68 +0.05 (+1.38%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$3.70 +0.01 (+0.41%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Cogent Biosciences NASDAQ:COGT$7.24 -0.02 (-0.28%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$7.24 0.00 (0.00%) As of 06/24/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Kura Oncology NASDAQ:KURA$5.98 +0.11 (+1.87%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$5.97 -0.01 (-0.17%) As of 06/24/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Avidity Biosciences NASDAQ:RNA$29.87 +0.72 (+2.47%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$30.06 +0.18 (+0.62%) As of 06/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
